- Home
- INDV vs RCUS Comparison
INDV vs RCUS Comparison
Compare INDV & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDV
- RCUS
- Stock Information
- Founded
- INDV 1994
- RCUS 2015
- Country
- INDV United States
- RCUS United States
- Employees
- INDV N/A
- RCUS N/A
- Industry
- INDV Biotechnology: Pharmaceutical Preparations
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- INDV Health Care
- RCUS Health Care
- Exchange
- INDV Nasdaq
- RCUS Nasdaq
- Market Cap
- INDV 1.3B
- RCUS 1.4B
- IPO Year
- INDV N/A
- RCUS 2018
- Fundamental
- Price
- INDV $11.65
- RCUS $14.02
- Analyst Decision
- INDV Strong Buy
- RCUS Buy
- Analyst Count
- INDV 2
- RCUS 12
- Target Price
- INDV $16.00
- RCUS $34.50
- AVG Volume (30 Days)
- INDV 1.2M
- RCUS 609.3K
- Earning Date
- INDV 02-20-2025
- RCUS 02-19-2025
- Dividend Yield
- INDV N/A
- RCUS N/A
- EPS Growth
- INDV N/A
- RCUS N/A
- EPS
- INDV N/A
- RCUS N/A
- Revenue
- INDV $1,182,000,000.00
- RCUS $263,000,000.00
- Revenue This Year
- INDV $6.13
- RCUS $127.65
- Revenue Next Year
- INDV N/A
- RCUS N/A
- P/E Ratio
- INDV N/A
- RCUS N/A
- Revenue Growth
- INDV 13.44
- RCUS 119.17
- 52 Week Low
- INDV $7.33
- RCUS $13.51
- 52 Week High
- INDV $23.22
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- INDV 49.25
- RCUS 37.13
- Support Level
- INDV $11.39
- RCUS $13.81
- Resistance Level
- INDV $12.75
- RCUS $14.52
- Average True Range (ATR)
- INDV 0.33
- RCUS 0.60
- MACD
- INDV -0.13
- RCUS -0.09
- Stochastic Oscillator
- INDV 34.52
- RCUS 22.97
About INDV Indivior PLC
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.